Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Sponsor
Han weidong (Other)
Overall Status
Unknown status
CT.gov ID
NCT01828008
Collaborator
(none)
20
25
Study Details
Study Description
Brief Summary
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Autologous CIK transfusion within 3 days post CD20 antibody treatment.
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
20 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Study Start Date
:
Apr 1, 2013
Anticipated Primary Completion Date
:
May 1, 2015
Anticipated Study Completion Date
:
May 1, 2015
Outcome Measures
Primary Outcome Measures
- disease free survival [5 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy
Exclusion Criteria:
- to refuse the therapy and need not tolerate the therapy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Han weidong
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Han weidong,
combination of anti-CD20 with CIK for refractory lymphomas,
Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT01828008
Other Study ID Numbers:
- BT-004
First Posted:
Apr 10, 2013
Last Update Posted:
Apr 10, 2013
Last Verified:
Jan 1, 2013
Keywords provided by Han weidong,
combination of anti-CD20 with CIK for refractory lymphomas,
Chinese PLA General Hospital
Additional relevant MeSH terms: